12 Health Care Stocks Moving In Friday’s Intraday Session
Gainers Intelligent Bio Solutions (NASDAQ:INBS) shares rose 108.5% to $5.03 during Friday’s regular session. The company’s market cap…
12 Health Care Stocks Moving In Monday’s After-Market Session
Gainers Akso Health Group (NASDAQ:AHG) stock increased by 23.4% to $1.32 during Monday’s after-market session. The market value…
12 Health Care Stocks Moving In Monday’s Pre-Market Session
Gainers Karuna Therapeutics (NASDAQ:KRTX) shares increased by 47.4% to $317.1 during Monday’s pre-market session. The company’s market cap…
Why AAR Shares Are Trading Lower By 7%? Here Are Other Stocks Moving In Friday’s Mid-Day Session
Shares of AAR Corp. (NYSE: AIR) fell during Friday’s session after the company reported mixed second-quarter financial results.
Why Rocket Lab Shares Are Trading Higher By 15%; Here Are 20 Stocks Moving Premarket
Shares of Rocket Lab USA, Inc. (NASDAQ: RKLB) shares rose sharply in pre-market trading after the company announced a new $515 million contract with a U.S. government customer.
12 Health Care Stocks Moving In Thursday’s After-Market Session
Gainers NuCana (NASDAQ:NCNA) shares rose 15.6% to $0.35 during Thursday’s after-market session. The market value of their outstanding…
12 Health Care Stocks Moving In Wednesday’s After-Market Session
Gainers Atara Biotherapeutics (NASDAQ:ATRA) shares moved upwards by 24.3% to $0.69 during Wednesday’s after-market session. The company’s market…
Atara Biotherapeutics Presents Preclinical Data On ATA3431, A Next-Generation Allogeneic CD20/CD19-Targeted CAR, At The 65th ASH Annual Meeting
ATA3431 Preclinical Data Demonstrates Superior In Vivo Anti-tumor Activity, Survival, and Functional Persistence Compared to Autologous CAR-T BenchmarkNo Observed Treatment-Related Toxicities or AlloreactivityData
12 Health Care Stocks Moving In Thursday’s Pre-Market Session
Gainers Dare Bioscience (NASDAQ:DARE) shares rose 31.1% to $0.46 during Thursday’s pre-market session. The company’s market cap stands…
Atara Biotherapeutics To Present New Tab-cel® Clinical Data During Oral Session At ESMO Immuno-Oncology Annual Congress 2023
Combined Analysis That Includes First Reported Data from Multicohort Phase 2 EBVision Trial Consistent with Previous Single-Center Experience
Pooled Analysis Shows 77.8% Objective Response Rate (ORR) in 18